Summary This latest Pharmaceutical and Healthcare disease pipeline guide Malignant Pleural Effusion - Pipeline Review, H2 2020, provides an overview of the Malignant Pleural Effusion (Respiratory) pipeline landscape.
Malignant pleural effusion is a condition in which cancer causes an abnormal amount of fluid to collect between the thin layers of tissue (pleura) lining the outside of the lung and the wall of the chest cavity. Lung cancer, breast cancer, lymphoma, and leukemia cause most malignant pleural effusions.
Report Highlights Pharmaceutical and Healthcare latest pipeline guide Malignant Pleural Effusion - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Malignant Pleural Effusion (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Malignant Pleural Effusion (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Malignant Pleural Effusion and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 4 and 2 respectively.
Malignant Pleural Effusion (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Malignant Pleural Effusion (Respiratory). - The pipeline guide reviews pipeline therapeutics for Malignant Pleural Effusion (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Malignant Pleural Effusion (Respiratory) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Malignant Pleural Effusion (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Malignant Pleural Effusion (Respiratory)
Reasons to Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Malignant Pleural Effusion (Respiratory). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Malignant Pleural Effusion (Respiratory) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Our reports have been used by over 10K customers, including:
Ureter Cancer - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Ureter Cancer - Pipeline Review, H2 2020, provides an overview of the Ureter Cancer (Oncology) pipeline landscape. Ureter cancer or ureteral cancer is cancer of the ureter. Symptoms...
Matrix Metalloproteinase 9 - Pipeline Review, H2 2020 Summary Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 18.104.22.168) - Matrix metallopeptidase 9 (MMP-9) is a matrixin that belong to the zinc-metalloproteinases family. It plays an essential...
C-C Chemokine Receptor Type 4 - Pipeline Review, H2 2020 Summary C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) pipeline Target constitutes close to 9 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The latest report...
Therapeutic Drug Monitoring Tests - Medical Devices Pipeline Assessment, 2020 Summary Medical Devices sector report, “Therapeutic Drug Monitoring Tests - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Therapeutic Drug Monitoring Tests pipeline products with...
200 pages •
By The Business Research Company
• Dec 2020
Major players in the arthritis monoclonal antibodies market are Johnson & Johnson, Roche, Novartis, Pfizer Inc, AbbVie Inc., Amgen Inc., Genentech, GSK, AstraZeneca PLC, and Mylan N.V. The global arthritis monoclonal antibodies market is expected to decline from $46.48 billion in 2019 to $45.18 billion in 2020 at a compound annual growth...
Obesity - Pipeline Review, H2 2020 Summary latest Pharmaceutical and Healthcare disease pipeline guide Obesity - Pipeline Review, H2 2020, provides an overview of the Obesity (Metabolic Disorders) pipeline landscape. Obesity is defined as having an excessive amount of body fat. Obesity increases...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.